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Abstract
OBJECTIVE: To explore the effect of antithymocyte
globulin (ATG)/antilymphocyte globulin (ALG) plus
kidney-nourishing Chinese medicinal (KNCM) on se-
vere aplastic anemia (SAA).
METHODS: Twenty-five subjects of severe aplastic
anemia were treated with ATG/ALD plus KNCM be-
tween 1992 and 2009, and the clinical data before
and after treatment were collected and analyzed.
RESULTS: Of the 25 patients, 9 were nearly cured, 6
were improved, 5 were in remission, and 5 failed.
The overall effective rate was 80.0% . The 3-year,
5-year, 10-year, 15-year survival rate were respec-
tively 98.6%, 97.3%, 97.3%, 67.5%, and median sur-
vival time was 180 months. Compared to the condi-
tions before administering the medication of ATG/
ALG plus KNCM, after 2 weeks, reticulocyte was first
improved (P=0.001); one month later, followed by
palette (P=0.037); two months later, by neutrophil
cell in peripheral blood (P=0.001); three months lat-
er, then by the hemoglobin (P=0.012). By conduct-
ing 1-year follow-up, 1 case of complication--parox-
ysmal nocturnal hemoglobinuria (PNH) was identi-
fied and the patient still alive today.
CONCLUSION: ATG/ALG plus KNCM had better ef-
fect on SAA and could improve patients' survival
rate.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Severe aplastic anemia (SAA) is a condition that may
acutely develop and have a relatively high mortality
rate. It is a refractory illness of hematological diseases.
Studies showed that most of aplastic anemia was
caused by immune disorder.1 The very severe aplastic
anemia (VSAA), a much more serous condition, is
characterized by higher death rate and often accompa-
nied by heavy infection and internal hemorrhage. 20
years ago, the mortality rate of VSAA was nearly 100%.
Based on VSAA's nature of acute onset, rapid develop-
ment, progressive anemia, high fever and severe hemor-
rhage, it was defined and discussed as "Ji lao", "Re
Lao" or "Xue Zheng" in Traditional Chinese Medicine
(TCM). In 2004, Hematolgical Committee of Chinese
Association of the Integration of Traditional and West-
ern Medicine defined SAA as "Ji Sui Lao" in terms of
TCM theory. The department of Xiyuan Hospital have
been engaged in the research into AA and it has treated
the illness with integration of TCM and Western Medi-
cines since 1950s2-3 and proposed the kidney-nourish-
ing as the primary principle in AA's treatment with
TCM, which has been acknowledged as a better
scheme for chronic aplastic anemia. Starting from
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1990s, antithymocyte globulin (ATG)/antilymphocyte
globulin (ALG) plus kidney-nourishing Chinese medic-
inal (KNCM) has been used as the first line treatment
for SAA and VSAA. Up to date, few reports have been
published on VSAA's treatment with ATG/ALG plus
KNCM. In this paper, we report our results of treating
VSAA with the integration of TCM with Western
Medicine from 1992 to 2009.
METHODS
Subjects
Twenty-seven subjects of type-I VSAA were recruited
by the Department of Hematology of Xiyuan Hospital
of Chinese Academy of Chinese Medicine Sciences. 2
of them dropped out after ATG administered for 2
months due to financial issue. 25 subjects, 17 males
and 8 females, were treated and evaluated. Their ages
ranged from 7 to 61 years with median age of 29, and
the disease courses ranged from 1 to 6 months with me-
dian course of 1.1 months. 11 cases were treated with
ATG (of them, 5 with horse anti-human antibody; 6
with rabbit anti-human antibody) and 14 cases were
treated with ALG.
Diagnostic criteria4
VSAA was diagnosed with Camitta's criteria (1925) for
SAA plus neutrophil count which was less than 0.2 ×
109/L.
Treatment
Administration of ATG/ALG: ALG (swine anti-human
T cell immunoglobulin, Wuhan Institute of biological
Products, P. R. China), intravenously guttae (iv gtt)
20-30 mg/(kg·d). ATG (horse anti-human T cell im-
munoglobulin, Genzyme Polyclonals S.A.S),iv gtt
8.3-13.4 mg/(kg·d); ATG (rabbit anti-human T cell
immunoglobulin, Genzyme Polyclonals S.A.S), iv gtt
2.5-3.2 mg/(kg·d), ATG (rabbit anti-human T cell im-
munoglobulin, Fresenius Biotech GmbH), iv gtt 5-
7 mg/(kg·d). After hypersensitive tests of the subjects
were confirmed negative, ATG/ALG were adminis-
tered, iv gtt QD, to them for 5 days. Every time prior to
the administration of ATG/ALG, 5 mg of Dexametha-
sone was administered by venous infusion and 25 mg of
promethazine hydrochloride by intramuscular injection.
Administration of KNCM: In terms of TCM theory,
kidney deficiency can be classified as kidney-Yang defi-
ciency and kidney-Yin deficiency. While the kidney
was nourished, spleen might be nourished and blood
activated, related toxic elements eliminated depending
on the outcome of pattern differentiation.
The commonly used Chinese medicinal were as fol-
lows: Radix Rehmannia, Fructus Corni, Polugo-
num Multiflorum Thunb, Fructus Psoralea, Cuscuta
Chinensis Lam, Radix morindae officinalis, Songaria
Cynomorium and Herba Epimedii.
Addition of extra medicinal was dependent on the out-
come of pattern differentiation: for the pattern with
manifest kidney deficiency, Fructus mori, Glossy privet
fruit, Manyflower solomonseal rhizome and Barbury
wolfberry fruit were added; for the pattern with mani-
fest kidney-Yang deficiency, Rhizoma curculiginis and
Herba cistanches were added. For the pattern accompa-
nied by symptoms of spleen deficiency, Radix pseu-
dostellariae, Largehead atractylodes rhizome, Common
yam rhizome was added; for the pattern accompanied
by the symptoms of blood deficiency, Astragalus mem-
branaceus, Chinese angelica, Chinese peony and Pla-
centa hominis were added. For the pattern accompa-
nied by blood stasis, Radix salviae miltiorrhiza, Millet-
tia dielsiana, Leonurus heterophullus and Rhizoma li-
gustici chuanxiong were added; for the pattern accom-
panied by heat toxin, Smilax glabra, Taraxacum, Flos
lonicerae and Weeping forsythia fruit were added. The
medicinal were decocted and taken twice a day in the
morning and evening respectively. The course of thera-
py was 6 months, and two consecutive courses were ad-
ministered. After finishing the two courses, all patients
who showed progression were required to be treated
with the same regimen for at least 1 year or more.
Supportive and palliative treatment: All patients that
underwent above-mentioned treatment were orally ad-
ministered Cyclosporin A. It was initially taken at the
dose of 6 mg/(kg·d) BID, then the dose was modified
in terms of blood drug concentration (to keep its
trough concentration at 200-400 ng/mL). The treat-
ment course was 6 month or more. After the hemo-
gram was stable, the dose was slowly reduced and final-
ly it ceased to be administered; Stanozolol (6-12 mg/d)
or testosterone undecanoate capsule (120- 240 mg/d)
was taken orally BID. After the peripheral hemogram
became normal, the dose of medicine was reduced
gradually and maintained for 3 years. Granulocyte-col-
ony stimulating factor was administered at the dose of
5 μg/(kg·d) until the count of neutrophilic granulo-
cytes was greater than 1×109/L; Blood transfusion was
performed when hemoglobin was below 60 g/L and
the count of platelets was less than10×109/L or when
there was a increasing tendency of hemorrhage, the ma-
chine-collected pallet was transfused.
Prevention and treatment of adverse reaction: When
ATG/ALG was used, patients were requested to stay in
the wards with 100-grade air cleanliness to be kept
away from infection. Their blood cell counts were ex-
amined every other day or daily when necessary. De-
pending on outcome of the hemogram, bone marrow
might be re-examined. Hypersensitiveness and serum
disease were monitored during the administration of
ATG/ALG. The symptoms watched were hypertricho-
sis, digestical tract disorders, hand tremor, periphery
sensation decreasing, pyrexia, bleeding, skin itch, myo-
salgia, arthrocele. Regularly hepatic and renal functions
were examined, electrocardiogram and X-ray were per-
formed, hemocluture was conducted, and chest CT
performed if necessary.
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Prevention and treatment of serum sickness: After
ATG/ALG treatment, Prednisone acetate was orally ad-
ministered at the dose of 50 mg/d. If serum sickness re-
action occurred, prednisone acetate was replaced with
methylprednisolone, which was administered at the
dose of 40-200 mg/d, iv gtt for no more than one
week, then its dose was gradually reduced. Once infec-
tion occurred, antibiotics were used. If hepatic func-
tion impairment occurred, Polyene Phosphatidylcho-
line and diammonium glycyrrihizinate were adminis-
tered for liver protection purpose.
Effect evaluation
The efficacy evaluation criteria was formulated based
on the evaluation standard formulated by the Fourth
National conference on Aplastic Anemia held in 1987,5
The efficacy was graded as cure, remittance, improve-
ment and failure. And the first 3 grades, cure, remit-
tance and improvement, were considered having effect.
Data analysis
SPSS 13.0 was employed for data analysis.
Matched-pair sample t-test was performed to compare
means before and after the treatment in the same
group. The difference was considered significant if
P-value was less than or equal to 0.05.
RESULTS
Effectiveness ATG/ALG plus KNCM in the treatment
of VSAA (Table 1)
Table 1 summarizes the information of the 25 VSAA
patients treated with the therapy and followed up for 1
year or more after they finished the intervention.
The change of hemograms before and after the
treatment of ATG/ALG plus KNCM (Table 2)
From Table 1, we can see that 2 months after the treat-
ment, the neutrophil started to rise significantly (P=
0.001); that hemoglobin increased manifestly 3
months after treatment (P=0.012); that reticulocyte be-
gan to go up quickly 2 weeks after the treatment (P=
0.001); that platelet rose considerably 1month after the
treatment (P=0.037).
Survival Curve for the treatment of ATG/ALG plus
KNCM (Figure 1)
From Figure 1, we can see that, after the Treatment of
ATG/ALG plus KNCM, the survival rate for 3 years, 5
years, 10 years and 15 years were 98.6% , 97.3% ,
97.3%, 67.5% respectively..
Adverse reaction and long-term complication
Allergic response occurred in 23 VSAA cases after
ATG/ALG administered. Of all patients of serum sick-
ness reaction; pyrexia occurred in 22 patients; skin rash
in 21 patients; arthrodynia in 19 patients; and chest
distress in 1 patient. After administered methylprednis-
olone, proazamine and calcium gluconate, all symp-
toms were improved. The serum sickness reaction oc-
Table 1 Effectiveness of ATG/ALG plus KNCM
VSAA
Cure
9/25 (36.0%)
Remittance
5/25 (20.0%)
Improvement
6/25 (24.0%)
Failure
5/25 (20.0%)
Effective rate
20/25 (80.0%)
Table 2 Comparison of blood cell counts before and after treatment ( xˉ ±s)
Notes: Compared with those before treatment, bP<0.05, a P<0.01.
Time point
Before Treatment
1 week after treatment
2 weeks after treatment
1 month after treatment
2 months after treatment
3 months after treatment
6 months after treatment
Neutrophil
(×109/L)
0.10±0.09
0.15±0.12
0.37±0.35
0.44±0.40
1.73±0.88a
1.65±0.55a
1.73±1.35a
Hemoglobin
(G/l)
68.48±18.10
70.11±8.28
76.20±16.18
74.20±13.61
77.50±42.19
79.11±7.36b
82.44±9.40b
Reticulocyte
(×109/L)
1.24±3.24
5.47±3.55
7.21±4.28a
10.11±8.27a
13.98±10.54a
15.88±12.71a
18.22±10.84a
Platelet
(×109/L)
14.89±14.76
23.44±15.77
22.67±12.78
30.22±28.76b
25.5±21.50b
29.0±16.99b
44.60±40.2a
Figure 1 Survival curve for the treatment of ATG/ALG plus
KNCM
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Notes: ATG/ALG: antithymocyte globulin/antilymphocyte globulin; KNCM: kidney-nourishing Chinese medicinalon; VSAA: very severe
aplastic anemia.
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curred as early as the first day after ATG/ALG was ad-
ministered and the latest one occurred on the 30th day
after ATG/ALG was given and the reaction lasted from
4-8h. The time period of follow-up ranged from 51 to
172 months. The median follow-up time was 104
months. During the follow-up period, patients 2 were
reported death. One relapsed and developed into
PNH, who is still alive today.
DISCUSSION
VSAA is a life-threatening disorder that the function of
bone marrow is impaired. The condition leads to red
marrow replaced by yellow marrow which is specialized
fat cells, and the decrease of the whole blood cells. In
many cases, the etiology is considered to be idiopathic,
but one known cause is an autoimmune disorder in
which T lymphocytes attack the bone marrow.6 Aplas-
tic anemia is sometimes associated with exposure to
toxins such as benzene, or with the use of certain
drugs, including chloramphenicol and carbamazepine.
Exposure to ionizing radiation from radioactive materi-
als or radiation-producing devices is also associated
with the development of VSAA.
There are few records of VSAA in the ancient litera-
tures. However, the Huangdi's Internal Classic has
many descriptions of grouping symptoms such as pale,
bleeding and pyrexia. In Han Dynasty, Zhongjing
Zhang first coined the word of Xulao for the condition
in Synopsis of Golden Chamber. In terms of TCM the-
ory, VSAA is a long-term course illness characterized
by the deficiency pattern staying throughout the whole
course, which involves the deficiency of heart, liver,
spleen, lung and kidney. Qi and blood deficiency ap-
peared first, then kidney deficiency, and essence deple-
tion follows. Although the condition involves heart, liv-
er, spleen and kidney, kidney has the closest relation
with VSAA. Kidney deficiency is the key factor under-
lying the onset and development of VSAA.
Currently, in China, the primary treatment for VSAA
is intensive immunosuppressive therapy (IST) such as
ATG/ALG and CsA. The fatality rate in early stage fell
to 9.6% . According to some early literature, the effi-
ciency rate of treating SAA with horse ATG only was
40%-50% and that with the combination of ATG and
CsA was 70% in the treatment period between 3 and 6
months. The advantage for the combination of the
medications is that ATG and CsA can act on different
part of immune system. Today, ATG/CsA is still used
in the regular treatment scheme for VSAA. Large num-
ber cases study in multi-centers proved that the effec-
tive rate of the treatment scheme was 70%7 with 5-year
survival rate up to 80%-90% .8 The research into the
treatment of VSAA with kidney-nourishing as princi-
ple method for AA started in 1960s. That the treat-
ment of AA should focus on kidney was first advocated
by the Hematolgical Committee of Chinese Associa-
tion of the Integration of Traditional and Western Med-
icine on the National Conference on Blood Disease
Treated by intetration of Chinese and Western Medi-
cines held in 1986 in Dalian, China. In terms of TCM
pattern differentiation for treatment, kidney deficiency
patterns for AA were classified into three: Yang deficien-
cy, Yin deficiency, both Yang and Yin deficiency. Ever
since the beginning of 1990s, combination of KNCM
and ATG/ALG for VSAA treatment was first used in
Xiyuan Hospital in Beijing, China. In our experience
of treating 25 VSAA patients, the total effective rate
was 80.0% . The survival rate for 3 years, 5 years, 10
years and 15 years were 98.6%, 97.3%, 97.3%, 67.5%
respectively. The reticulocyte, platelet, neutrophil and
hemoglobin started to rise 2 weeks, 1 months, 2
months and 3 months after the treatment respectively.
The results suggested that kidney-nourishing medicinal
played a vital role in the VSAA treatment and patients'
survival time.
For human body, ATG/ALG is a kind of heterogenous
protein, it mainly composes of IgG, which underlie the
allergy and serum sickness. Our study found that the
symptoms could disappear within 2-4 days of all pa-
tients experienced allergy (23/25,92.0% ), especially
2-8h after ATG/ALG first used, by slowing down
iv-gtt speed of ATG/ALG or stopping using it and tak-
ing medication such as dexamethasone. Serum sickness
is a systemic allergic disease caused by blood circula-
tion of allergen. It would occur 7-14 days after ATG/
ALG was given.9 The main symptoms were pyrexia,
rash, muscular soreness and anthralgia. Prednisolone
could bring serum sickness reaction under control at
the dose of 40-200 mg/d and larger dose was seldom
used. No sequela was found. So ALG/ATG is safe in
clinical practice.
The most important factor affecting the prognosis of
the patients treated with ATG is relapse. In Europe,
the reported rate was 30%-40% . The primary symp-
toms are red blood cell dependence and palette transfu-
sion dependence, and CsA dependence recurring.6 The
long-term (10 years) relapse rate is 33%, with median
relapse time of 570 day.10 Sometimes, a few VSAA pa-
tients, staying in remittance for ten years after IST ther-
apy, developed into clonal diseases such as PNH,
MDS, AML and other tumors. The occurrence of
PNH is 9% 11 and the 10-year cumulative incidence
was 16%.12 Another study reported that the incidence
of clonal disease was 10%-40%.13-14
In our study, 25 VSAA patients were followed up for at
least 1-year, no relapse was found. Only 1 case devel-
oped into PNH. Probably, the fewer relapse cases were
due to shorter follow-up period. Longer follow-up peri-
od will still be conducted. In spite of this, the treat-
ment of VSAA with ATG/ALG kidney-nourishing plus
Chinese medicinal already showed promising efficacy.
Moreover, up to date, no subjects have found dead.
Further study will try to explore how VSAA exert its
impact on complications.
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